Clinical Safety and Tolerability of New Specialized Food Product

The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study was to assess clinical safety and tolerability of newly developed specialized food product “SPP2” in patients with non-alcoholic steatohepatitis. New sp...

Full description

Saved in:
Bibliographic Details
Published inCurrent developments in nutrition Vol. 6; no. Supplement_1; p. 319
Main Authors Morozov, Sergey, Sasunova, Armida, Isakov, Vasily
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Inc 01.06.2022
Oxford University Press
Subjects
Online AccessGet full text
ISSN2475-2991
2475-2991
DOI10.1093/cdn/nzac053.060

Cover

Abstract The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study was to assess clinical safety and tolerability of newly developed specialized food product “SPP2” in patients with non-alcoholic steatohepatitis. New specialized food product (SPP2) was developed based on literature data on the efficacy of active biological compounds on pathogenesis of NASH. It contains: protein, fat, ω-3 PUFAs, carbohydrates, soluble fibre, Coenzime Q10, L-carnitine, α-lipoic acid, vitamins (A, B1, B2, B6, PP, B12, D3, C, K), phospholipids. The test batch of the product passed laboratory control for biological and toxicological safety. The study was approved by LEC and registered (NCT04308980). Patients with NASH (per EASL), were invited to participate and were randomized to receive iso-caloric diet alone (ICD) or iso-caloric diet and SPP2 (SPP2). Energy value of the diet was amended by calorie content of SPP2. The patients were advised to follow usual physical activity and report any adverse events (AE) occurred during the study. Organoleptic assessment with the use of 5-point Likert scale and repeated blood tests on chemistry and hematology were performed at baseline (BL) and after 14 days (EOT) of treatment. Non-parametric statistics was used for the analysis One subject was lost to follow-up in ICD group and one postponed the use of SPP2 due to the not related to safety reasons. The data of 25 subjects were available for the final analysis. The ICD (n = 8) and SPP2 (n = 17) groups did not differ by demographic and baseline characteristics. Adherence to diet was 88% in ICD and 92% in SPP2 groups, p = 0.7. Compliance with SPP was 97%. No serious adverse events occurred during the study. Organoleptic assessment of SPP2 initially: appearance (Mean ± SD) 3.9 ± 0.83 points; color 4.0 ± 0.5; aroma 3.6 ± 0.9; texture 3.7 ± 0.8; taste 3.9 ± 0.7; resulting in a mean score 3.9 ± 0.4 point at BL. No dissatisfaction revealed at EOT: the mean organoleptic score was 4.2 ± 0.7 points (P = 0.07). No laboratory AEs occurred. New specialized food product “SPP2” in combination with iso-calorie diet is safe and well-tolerated by patients with NASH. Ministry of Science and Higher Education of Russia, FGMF-2022–0005.
AbstractList Objectives The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study was to assess clinical safety and tolerability of newly developed specialized food product “SPP2” in patients with non-alcoholic steatohepatitis. Methods New specialized food product (SPP2) was developed based on literature data on the efficacy of active biological compounds on pathogenesis of NASH. It contains: protein, fat, ω-3 PUFAs, carbohydrates, soluble fibre, Coenzime Q10, L-carnitine, α-lipoic acid, vitamins (A, B1, B2, B6, PP, B12, D3, C, K), phospholipids. The test batch of the product passed laboratory control for biological and toxicological safety. The study was approved by LEC and registered (NCT04308980). Patients with NASH (per EASL), were invited to participate and were randomized to receive iso-caloric diet alone (ICD) or iso-caloric diet and SPP2 (SPP2). Energy value of the diet was amended by calorie content of SPP2. The patients were advised to follow usual physical activity and report any adverse events (AE) occurred during the study. Organoleptic assessment with the use of 5-point Likert scale and repeated blood tests on chemistry and hematology were performed at baseline (BL) and after 14 days (EOT) of treatment. Non-parametric statistics was used for the analysis Results One subject was lost to follow-up in ICD group and one postponed the use of SPP2 due to the not related to safety reasons. The data of 25 subjects were available for the final analysis. The ICD (n = 8) and SPP2 (n = 17) groups did not differ by demographic and baseline characteristics. Adherence to diet was 88% in ICD and 92% in SPP2 groups, p = 0.7. Compliance with SPP was 97%. No serious adverse events occurred during the study. Organoleptic assessment of SPP2 initially: appearance (Mean ± SD) 3.9 ± 0.83 points; color 4.0 ± 0.5; aroma 3.6 ± 0.9; texture 3.7 ± 0.8; taste 3.9 ± 0.7; resulting in a mean score 3.9 ± 0.4 point at BL. No dissatisfaction revealed at EOT: the mean organoleptic score was 4.2 ± 0.7 points (P = 0.07). No laboratory AEs occurred. Conclusions New specialized food product “SPP2” in combination with iso-calorie diet is safe and well-tolerated by patients with NASH. Funding Sources Ministry of Science and Higher Education of Russia, FGMF-2022–0005.
The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study was to assess clinical safety and tolerability of newly developed specialized food product “SPP2” in patients with non-alcoholic steatohepatitis. New specialized food product (SPP2) was developed based on literature data on the efficacy of active biological compounds on pathogenesis of NASH. It contains: protein, fat, ω-3 PUFAs, carbohydrates, soluble fibre, Coenzime Q10, L-carnitine, α-lipoic acid, vitamins (A, B1, B2, B6, PP, B12, D3, C, K), phospholipids. The test batch of the product passed laboratory control for biological and toxicological safety. The study was approved by LEC and registered (NCT04308980). Patients with NASH (per EASL), were invited to participate and were randomized to receive iso-caloric diet alone (ICD) or iso-caloric diet and SPP2 (SPP2). Energy value of the diet was amended by calorie content of SPP2. The patients were advised to follow usual physical activity and report any adverse events (AE) occurred during the study. Organoleptic assessment with the use of 5-point Likert scale and repeated blood tests on chemistry and hematology were performed at baseline (BL) and after 14 days (EOT) of treatment. Non-parametric statistics was used for the analysis One subject was lost to follow-up in ICD group and one postponed the use of SPP2 due to the not related to safety reasons. The data of 25 subjects were available for the final analysis. The ICD (n = 8) and SPP2 (n = 17) groups did not differ by demographic and baseline characteristics. Adherence to diet was 88% in ICD and 92% in SPP2 groups, p = 0.7. Compliance with SPP was 97%. No serious adverse events occurred during the study. Organoleptic assessment of SPP2 initially: appearance (Mean ± SD) 3.9 ± 0.83 points; color 4.0 ± 0.5; aroma 3.6 ± 0.9; texture 3.7 ± 0.8; taste 3.9 ± 0.7; resulting in a mean score 3.9 ± 0.4 point at BL. No dissatisfaction revealed at EOT: the mean organoleptic score was 4.2 ± 0.7 points (P = 0.07). No laboratory AEs occurred. New specialized food product “SPP2” in combination with iso-calorie diet is safe and well-tolerated by patients with NASH. Ministry of Science and Higher Education of Russia, FGMF-2022–0005.
Abstract Objectives The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study was to assess clinical safety and tolerability of newly developed specialized food product “SPP2” in patients with non-alcoholic steatohepatitis. Methods New specialized food product (SPP2) was developed based on literature data on the efficacy of active biological compounds on pathogenesis of NASH. It contains: protein, fat, ω-3 PUFAs, carbohydrates, soluble fibre, Coenzime Q10, L-carnitine, α-lipoic acid, vitamins (A, B1, B2, B6, PP, B12, D3, C, K), phospholipids. The test batch of the product passed laboratory control for biological and toxicological safety. The study was approved by LEC and registered (NCT04308980). Patients with NASH (per EASL), were invited to participate and were randomized to receive iso-caloric diet alone (ICD) or iso-caloric diet and SPP2 (SPP2). Energy value of the diet was amended by calorie content of SPP2. The patients were advised to follow usual physical activity and report any adverse events (AE) occurred during the study. Organoleptic assessment with the use of 5-point Likert scale and repeated blood tests on chemistry and hematology were performed at baseline (BL) and after 14 days (EOT) of treatment. Non-parametric statistics was used for the analysis Results One subject was lost to follow-up in ICD group and one postponed the use of SPP2 due to the not related to safety reasons. The data of 25 subjects were available for the final analysis. The ICD (n = 8) and SPP2 (n = 17) groups did not differ by demographic and baseline characteristics. Adherence to diet was 88% in ICD and 92% in SPP2 groups, p = 0.7. Compliance with SPP was 97%. No serious adverse events occurred during the study. Organoleptic assessment of SPP2 initially: appearance (Mean ± SD) 3.9 ± 0.83 points; color 4.0 ± 0.5; aroma 3.6 ± 0.9; texture 3.7 ± 0.8; taste 3.9 ± 0.7; resulting in a mean score 3.9 ± 0.4 point at BL. No dissatisfaction revealed at EOT: the mean organoleptic score was 4.2 ± 0.7 points (P = 0.07). No laboratory AEs occurred. Conclusions New specialized food product “SPP2” in combination with iso-calorie diet is safe and well-tolerated by patients with NASH. Funding Sources Ministry of Science and Higher Education of Russia, FGMF-2022–0005.
Author Isakov, Vasily
Sasunova, Armida
Morozov, Sergey
Author_xml – sequence: 1
  givenname: Sergey
  surname: Morozov
  fullname: Morozov, Sergey
  organization: Federal Research Center of Nutrition and Biotechnology
– sequence: 2
  givenname: Armida
  surname: Sasunova
  fullname: Sasunova, Armida
  organization: Federal Research Center of Nutrition and Biotechnology
– sequence: 3
  givenname: Vasily
  surname: Isakov
  fullname: Isakov, Vasily
  organization: Federal Research Center of Nutrition and Biotechnology
BookMark eNqNkV1L5DAUhsOisH5d723BO2FmkpxpO7kRZdBVEBV0r8NpcrIbrUlNW2X89VvpgB8X4lVC8j4vJ0-22UaIgRj7JfhUcAUzY8MsvKDhOUx5wX-wLTkv84lUSmy82_9ke217xzkXSqmCqy12tKx98Abr7AYddasMg81uY00JK1_74SC67JKes5uGjMfav5DNTmO02XWKtjfdLtt0WLe0t1532J_Tk9vl2eTi6vf58vhiYqQq-cQ5KLHiuXQIVW6sUxaFQTcvqgUAXwgowEhAtbAA5TyXVSUXBFI4WUhwBDuMj719aHD1jHWtm-QfMK204PpVgh4k6LUEPUgYkMMRafrqgayh0CV8wyJ6_fEm-H_6b3zSSiiAXA4F--uCFB97ajt9F_sUhmdqEIXKhcqhHFKzMWVSbNtE7huDHYxE7JtvhNUYpsHuk6ekW-MpGLI-kem0jf4LtvzEmvV339PqS_I_f5i6UA
ContentType Journal Article
Copyright 2022 American Society for Nutrition.
The Author 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. 2022
The Author 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2022 American Society for Nutrition.
– notice: The Author 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. 2022
– notice: The Author 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 6I.
AAFTH
TOX
AAYXX
CITATION
3V.
7RV
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
5PM
ADTOC
UNPAY
DOI 10.1093/cdn/nzac053.060
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
Oxford Journals Open Access Collection
CrossRef
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
DatabaseTitleList Publicly Available Content Database



Database_xml – sequence: 1
  dbid: TOX
  name: Oxford Journals Open Access Collection
  url: https://academic.oup.com/journals/
  sourceTypes: Publisher
– sequence: 2
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 3
  dbid: BENPR
  name: ProQuest Central - New (Subscription)
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2475-2991
EndPage 319
ExternalDocumentID 10.1093/cdn/nzac053.060
PMC9193352
10_1093_cdn_nzac053_060
S2475299123133385
GroupedDBID .1-
.FO
0R~
7RV
7X7
8FI
8FJ
AAFWJ
AAHBH
AALRI
AAPXW
AAVAP
AAXUO
AAYWO
ABPTD
ABUWG
ABXVV
ACGFS
ACVFH
ADBBV
ADCNI
ADVLN
AEUPX
AFJKZ
AFKRA
AFPKN
AFPUW
AFRHN
AIGII
AITUG
AJUYK
AKBMS
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMNDL
AMRAJ
AOIJS
APXCP
BAYMD
BCNDV
BENPR
CCPQU
EBS
EJD
EMOBN
FDB
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
IAO
IHR
INH
ITC
KSI
M~E
NAPCQ
O9-
OK1
PHGZM
PHGZT
PIMPY
PPXIY
PUEGO
RPM
UKHRP
Z5R
6I.
AAFTH
ABDBF
AFCTW
AFULF
BTTYL
OJZSN
ROX
TOX
0SF
AAYXX
CITATION
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c2970-ff37ab052fa3b5cdf9da1caf46b833081363c23a98d337452bb28e321f2623fe3
IEDL.DBID 7X7
ISSN 2475-2991
IngestDate Mon Sep 15 10:01:21 EDT 2025
Tue Sep 30 17:06:26 EDT 2025
Fri Sep 19 20:53:59 EDT 2025
Wed Oct 01 01:49:16 EDT 2025
Wed Aug 28 03:17:35 EDT 2024
Fri Feb 23 02:36:31 EST 2024
Tue Aug 26 16:32:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Supplement_1
Language English
License http://creativecommons.org/licenses/by-nc-nd/4.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2970-ff37ab052fa3b5cdf9da1caf46b833081363c23a98d337452bb28e321f2623fe3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
OpenAccessLink https://www.proquest.com/docview/3169519537?pq-origsite=%requestingapplication%
PQID 3169519537
PQPubID 7121353
PageCount 1
ParticipantIDs unpaywall_primary_10_1093_cdn_nzac053_060
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9193352
proquest_journals_3169519537
crossref_primary_10_1093_cdn_nzac053_060
oup_primary_10_1093_cdn_nzac053_060
elsevier_sciencedirect_doi_10_1093_cdn_nzac053_060
elsevier_clinicalkey_doi_10_1093_cdn_nzac053_060
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20220601
PublicationDateYYYYMMDD 2022-06-01
PublicationDate_xml – month: 06
  year: 2022
  text: 20220601
  day: 01
PublicationDecade 2020
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
PublicationTitle Current developments in nutrition
PublicationYear 2022
Publisher Elsevier Inc
Oxford University Press
Publisher_xml – name: Elsevier Inc
– name: Oxford University Press
SSID ssj0001999609
Score 2.187774
Snippet The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study was to...
Abstract Objectives The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of...
Objectives The use of specialized food products may increase efficacy of treatment in patients with non-alcoholic steatohepatitis (NASH). The aim of the study...
SourceID unpaywall
pubmedcentral
proquest
crossref
oup
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 319
SubjectTerms Dietary Bioactive Components
Food products
SummonAdditionalLinks – databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEB_q9UFf1FrFq7UEFNGH_Uiym-y-eUiPUrAUegf1KeSTFs_do71D7v56k_04eoVaBJ83k81OZie_TGZ-AfgYXCApNY-Uy3WUWVxEErPc2zJ2WUqpLnSoRv5-xk6m2ellfrkDk74WRnZZ4fGmpMFUSafEaG5cwpLmussmdiZw4i0oCRR3oQA0qdZSe6OKU5bGvu0T2GXh2GkAu9Oz89GPcM9cxvPIe2Dcs_yUtHnDHcmHFqit-rcAQ-8nUT5dVnO5-i1nszsr1PgFLPtvaxNTfsbLhYr1-h7t4__--JfwvIO0aNT2sAc7tnoF-6PKb-d_rdAn1CSZNtH7ffja8ZDO0IV0drFCsjJoUs_sTcsXvkK1Q97xoou5DcH867U1aFzXBp231LSvYTo-nnw7ibpLHCJNSp5GzlEuVZoTJ6nKtXGlkVhLlzFVUOoBCWVUEyrLwlDKs5woRQpLCXbEIzNn6RsYVHVl3wKymd9tqdwQ5WgmLSsw15zLvFA4M5oVQ_jcz5yYt1wdoj1jp8JrUnQaEl5DQ0j7mRV9Cap3msKvIw-LkI1Ih05a1PF3oQ9-Lh8fzWFvVqJzIbeCYlYG6h_Kh8C3TG3TXaAG335SXV81FOGlx-UeWg_hy8YoHxvEwT-0fQfPSCgDaaJRhzBY3Cztew_OFuqo-9f-ABU2Ojc
  priority: 102
  providerName: Unpaywall
Title Clinical Safety and Tolerability of New Specialized Food Product
URI https://www.clinicalkey.com/#!/content/1-s2.0-S2475299123133385
https://dx.doi.org/10.1093/cdn/nzac053.060
https://www.proquest.com/docview/3169519537
https://pubmed.ncbi.nlm.nih.gov/PMC9193352
https://academic.oup.com/cdn/article-pdf/6/Supplement_1/319/44040997/nzac053.060.pdf
UnpaywallVersion publishedVersion
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2475-2991
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999609
  issn: 2475-2991
  databaseCode: DOA
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2475-2991
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999609
  issn: 2475-2991
  databaseCode: M~E
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2475-2991
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001999609
  issn: 2475-2991
  databaseCode: RPM
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2475-2991
  dateEnd: 20221231
  omitProxy: true
  ssIdentifier: ssj0001999609
  issn: 2475-2991
  databaseCode: 7X7
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central - New (Subscription)
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2475-2991
  dateEnd: 20221231
  omitProxy: true
  ssIdentifier: ssj0001999609
  issn: 2475-2991
  databaseCode: BENPR
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3fb9MwELZge4AXxBiIwqgsgRA8hMZ2EidPrEOrJiRKBa1Uniz_1CYVp2ydUPfXc06cbkWwveQh0UXW3fn8-ez7DqE3IQTSSvNEuVwnmSVlIkmRgy8Tl6WM6VKHauQv4-Jkln2e5_OYcLuI1yq7mNgEalPrkCMfMFJUgQmF8Y_LX0noGhVOV2MLjftolwBUCV7N5_w6xxLQfFp1jD4VG2jjB_5KanC9D2lDS_nPxWir1i1Azr8vTD649Eu5_i0Xixur0egxehRhJB62dt9D96x_gvaHHrbQP9f4LW4udjYZ8310GLk_F_i7dHa1xtIbPK0X9rzl6F7j2mEIdjj2oj-7sgaP6trgSUsH-xTNRsfTTydJbJyQaFrxNHGOcanSnDrJVK6Nq4wkWrqsUCVjAAJYwTRlsioNYzzLqVK0tIwSRwENOcueoR1fe_scYZvBDkflhirHMmmLknDNucxLRTKji7KH3nUaFMuWH0O059pMgLJFVLYAZfdQ2mlYdGWfEKgExO7_i9CNSEQE7Up_u9BrMN_doznozCvitL0Q107WQ3zL5JvfBTru7S_-7LSh5a4ACwOc7aH3G-e4axAvbh_ES_SQhmqLJulzgHZW55f2FWCgleo3jt5Hu0fH48m3fpNJgOf06xzezcaT4Y8_MuANsA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VciiXCiiIbQu1xENwCBs_EicHBFVhtaUPIXUr7c34KSptk6Xdqkp_FL8RO48ti6A99RzZsma-jL8Zez4DvAohkOSaR8olOmIWZ5HEaeKxjB2LKdWZDt3IB4fp8Jh9HSfjJfjV9cKEa5VdTKwDtSl1qJH3KU7zoIRC-cfpzyi8GhVOV7snNBpY7Nnq0qds5x92P3v_viZk8GW0M4zaVwUiTXIeR85RLlWcECepSrRxuZFYS8dSlfnkPsM0pZpQmWeGUs4SohTJLCXYEU8VnKV-3ntwn9GYBa1-PubXNZ2QPcR5pyCU0742Rb-4ktpD_X1cy2D-c_Nb6K0LFPfvC5orF8VUVpdyMvlj9xs8hNWWtqLtBmePYMkWj2Ftu_Ap-2mF3qD6ImldoV-DT63W6AQdSWdnFZKFQaNyYs8aTfAKlQ754IqOpjYU7E-urEGDsjToWyM_-wSO78SkT2G5KAv7DJBlPqNSiSHKUSZtmmGuOZdJpjAzOs168LazoJg2ehyiOUenwhtbtMYW3tg9iDsLi67N1AdG4feK_w8h8yEtA2mYxc2DXnr33b6azc69og0T5-Ia1D3gCy6fTxfkvxe_FCc_ahnw3HNvT5978G4OjtsWsX7zIrZgZTg62Bf7u4d7G_CAhE6PuuC0Ccuzswv73POvmXpRgx7B97v-y34DqTlEtw
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEB_q9UFf1FrFq7UEFNGH_Uiym-y-eUiPUrAUegf1KeSTFs_do71D7v56k_04eoVaBJ83k81OZie_TGZ-AfgYXCApNY-Uy3WUWVxEErPc2zJ2WUqpLnSoRv5-xk6m2ellfrkDk74WRnZZ4fGmpMFUSafEaG5cwpLmussmdiZw4i0oCRR3oQA0qdZSe6OKU5bGvu0T2GXh2GkAu9Oz89GPcM9cxvPIe2Dcs_yUtHnDHcmHFqit-rcAQ-8nUT5dVnO5-i1nszsr1PgFLPtvaxNTfsbLhYr1-h7t4__--JfwvIO0aNT2sAc7tnoF-6PKb-d_rdAn1CSZNtH7ffja8ZDO0IV0drFCsjJoUs_sTcsXvkK1Q97xoou5DcH867U1aFzXBp231LSvYTo-nnw7ibpLHCJNSp5GzlEuVZoTJ6nKtXGlkVhLlzFVUOoBCWVUEyrLwlDKs5woRQpLCXbEIzNn6RsYVHVl3wKymd9tqdwQ5WgmLSsw15zLvFA4M5oVQ_jcz5yYt1wdoj1jp8JrUnQaEl5DQ0j7mRV9Cap3msKvIw-LkI1Ih05a1PF3oQ9-Lh8fzWFvVqJzIbeCYlYG6h_Kh8C3TG3TXaAG335SXV81FOGlx-UeWg_hy8YoHxvEwT-0fQfPSCgDaaJRhzBY3Cztew_OFuqo-9f-ABU2Ojc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Safety+and+Tolerability+of+New+Specialized+Food+Product&rft.jtitle=Current+developments+in+nutrition&rft.au=Morozov%2C+Sergey&rft.au=Sasunova%2C+Armida&rft.au=Isakov%2C+Vasily&rft.date=2022-06-01&rft.pub=Elsevier+Inc&rft.issn=2475-2991&rft.eissn=2475-2991&rft.volume=6&rft.spage=319&rft.epage=319&rft_id=info:doi/10.1093%2Fcdn%2Fnzac053.060&rft.externalDocID=S2475299123133385
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2475-2991&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2475-2991&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2475-2991&client=summon